Immunome

CIK 0001472012 · IMNM Nasdaq

SIC
2834 · Pharmaceutical Preparations
Type
Operating
Status
Public
Filer
Non-accelerated filer
Incorporated
Delaware
FY End
Dec 31

Business Summary

Immunome, Inc. is a clinical-stage biotechnology company focused on developing first-in-class and best-in-class targeted oncology therapies, with deep expertise in antibody-drug conjugates (ADCs) and other oncology modalities. The company's lead asset, varegacestat (formerly AL102, acquired from Ayala Pharmaceuticals in March 2024), is an oral gamma secretase inhibitor that achieved highly significant Phase 3 results in December 2025 for desmoid tumors, with an NDA submission planned for Q2 2026. Immunome has no approved products and no product revenue to date, carrying an accumulated deficit of $728.2 million as of December 31, 2025.

Products & Services

Clinical Stage: - Varegacestat — oral, once-daily gamma secretase inhibitor (GSI) for desmoid tumors; Phase 3 RINGSIDE trial met all primary and key secondary endpoints (84% reduction in progression risk vs. placebo, HR=0.16; ORR 56% vs. 9%); NDA submission targeted Q2 2026 - IM-1021 — ROR1-targeting ADC utilizing proprietary HC74 TOP1 inhibitor...

Get a free account in seconds to read the full business overview. Create free account

AI-generated summary of Item 1 (Business) from the 10-K filed Mar 3, 2026 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.

Across SEC filings

Institutional holders · 13F

Q3 2026
210 managers reported a position for Q3 2026 +8 vs Q2 2026
Largest Q3 2026 Form 13F holders of Immunome by reported value
Largest holders Reported value
T Rowe Price Investment Management Inc $434.7M
FMR LLC $366.5M
BlackRock Inc $192.1M
WELLINGTON MANAGEMENT GROUP LLP $129.9M
DRIEHAUS CAPITAL MANAGEMENT LLC $107.1M

Annual results · 10-K

Fiscal 2025
Revenue
$6.9M
Net loss
-$212.4M

As reported in the fiscal 2025 annual report.

Funds & ETFs · N-PORT

218 funds
Largest fund holders reported on Form N-PORT
Fund Value % of fund
T. Rowe Price Small-Cap Stock Fund, Inc. $152.1M 1.64%
Fidelity Growth Company Fund $134.4M 0.14%
VANGUARD HEALTH CARE FUND $84.3M 0.22%
PRIMECAP Odyssey Aggressive Growth Fund $84.1M 1.14%
T. Rowe Price Institutional Small-Cap Stock Fund $82.8M 1.65%
VANGUARD TOTAL STOCK MARKET INDEX FUND VTI $68.3M < 0.01%
State Street(R) SPDR(R) S&P(R) Biotech ETF XBI $63.4M 0.59%
Select Biotechnology Portfolio $58.4M 0.93%
iShares Russell 2000 ETF IWM $58.2M 0.07%
Fidelity Growth Company K6 Fund $38.8M 0.14%

218 funds reported holding $1.3B in total on their latest public Form N-PORT reports, the most recent dated September 2026. Security record

Insider trades · Form 4

-$25.2M net open-market insider transactions, last 12 months 8 filings with purchases ($2.1M), 15 filings with sales ($27.3M)

Latest filings

5%+ holders · 13D/G

7 filers
Schedule 13D and 13G filers reporting a stake of 5% or more
Filer % of class Filed
WELLINGTON MANAGEMENT GROUP LLP 13G 5.3% 2026-11-16
VANGUARD CAPITAL MANAGEMENT LLC 13G 5.0% 2026-10-30
T Rowe Price Investment Management Inc 13G 17.4% 2026-08-14
Enavate Sciences GP LLC 13D 4.3% 2025-12-22
FMR LLC 13G 15.0% 2025-10-07
JANUS HENDERSON GROUP PLC 13G 2.2% 2025-05-14
Immunome Aggregator LP 13D 6.0% 2025-02-04

Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.

Federal lobbying · LD-2

$10.0K reported spend, four quarters through Q1 2023

Securities

Securities issued by this company
CUSIP Security Type
45257U108 IMNM IMMUNOME INC Common stock

Latest SEC filings

All filings →
Latest SEC filings by Immunome
Form Description Filed
SCHEDULE 13G SCHEDULE 13G 2026-11-16
S-3ASR S-3ASR 2026-11-09
S-3ASR S-3ASR 2026-11-09
10-Q Quarterly Report 2026-11-09
8-K Current Report 2026-11-09
SCHEDULE 13G SCHEDULE 13G 2026-10-30
8-K Current Report 2026-10-05
4 Insider Transaction · Jack Higgins 2026-09-15
144 144 2026-09-11
SCHEDULE 13G/A SCHEDULE 13G/A 2026-08-14
Loading ownership data...
Loading insider trading data...
Loading financials...

Quality is a Plus feature

See why the score is what it is — the score history and the full test-by-test breakdown behind the composite.

Valuation is a Premium feature

What this company is worth versus its price — fair value at today's bond rate, margin of safety, and the Graham Number against the institutional consensus price.

Loading SEC filings...
Loading sponsor profile...